Real-world evaluation of ImmuCare-PRO patient-reported outcomes in melanoma patients treated with immune checkpoint inhibitors

Real-world evaluation of ImmuCare-PRO patient-reported outcomes in melanoma patients treated with immune checkpoint inhibitors

Background: Toxicity profile of immune checkpoint inhibitors (ICI) poses challenges for early detection of immune-related adverse events (IrAEs). In oncology, patient-reported outcomes (PROs) are reported to have a beneficial effect; however, their efficacy for IrAE detection in melanoma patients re...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Belkaïd, S. Milley, R. Saux, M. Bonjour, A. Augros, P.-J. Souquet, D. Maillet, D. Maucort-Boulch, C. Dolla, L. Thomas, S. Dalle
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
immune checkpoint inhibitors
patient-reported outcome measures
melanoma
risk management
surveys and questionnaires
remote patient monitoring
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820124000687
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2949820124000687

Similar Items